Eagle Ridge Investment Management Sells 1,458 Shares of Hologic, Inc. (NASDAQ:HOLX)

Eagle Ridge Investment Management cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 193,728 shares of the medical equipment provider’s stock after selling 1,458 shares during the period. Eagle Ridge Investment Management owned approximately 0.09% of Hologic worth $13,966,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of HOLX. Sanctuary Advisors LLC acquired a new position in Hologic during the 2nd quarter worth approximately $1,212,000. Czech National Bank increased its stake in Hologic by 6.4% in the 3rd quarter. Czech National Bank now owns 47,316 shares of the medical equipment provider’s stock valued at $3,854,000 after buying an additional 2,843 shares during the last quarter. GAMMA Investing LLC increased its stake in Hologic by 17.9% in the 3rd quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after buying an additional 582 shares during the last quarter. Marcum Wealth LLC bought a new stake in Hologic during the 3rd quarter worth about $202,000. Finally, Wedmont Private Capital boosted its stake in shares of Hologic by 3.7% during the 3rd quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock worth $361,000 after buying an additional 162 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.88% of the stock is owned by company insiders.

Hologic Stock Performance

Shares of Hologic stock opened at $65.45 on Friday. The company’s 50 day moving average price is $72.63 and its two-hundred day moving average price is $77.86. The firm has a market capitalization of $14.77 billion, a P/E ratio of 19.65, a P/E/G ratio of 2.35 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic, Inc. has a fifty-two week low of $64.87 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. On average, equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on HOLX shares. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Wolfe Research began coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating on the stock. UBS Group lifted their target price on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a report on Monday. Finally, JPMorgan Chase & Co. upped their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Nine equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $85.77.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.